<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3939">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04414631</url>
  </required_header>
  <id_info>
    <org_study_id>2020-01252; me20Osthoff3</org_study_id>
    <nct_id>NCT04414631</nct_id>
  </id_info>
  <brief_title>Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19</brief_title>
  <official_title>Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial (PROTECT-COVID-19).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharming Technologies B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to analyze if administration of conestat alfa for 72 hours in&#xD;
      addition to standard of care (SOC) in patients hospitalized with non-critical SARS-CoV-2&#xD;
      pneumonia (WHO Ordinal Scale Score 3 or 4) reduces the risk of disease progression to Acute&#xD;
      Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic hyperinflammation is a hallmark of more severe stages of COVID-19 leading to acute&#xD;
      respiratory distress syndrome, mechanical ventilation and ultimately death. In this stage,&#xD;
      COVID-19 is associated with a decrease in suppressor and regulatory T cell counts and an&#xD;
      extensive release of proinflammatory cytokines and biomarkers called a cytokine storm, which&#xD;
      is thought to be the major driver of severe pneumonia caused by SARS-CoV-2. C1 esterase&#xD;
      inhibitor (C1INH) is a member of the serpin superfamily of serine-protease inhibitors and is&#xD;
      a strong inhibitor of the complement System (CS) and the kinin-kallikrein (KK) System.&#xD;
      Conestat alfa is a recombinant human C1INH, that shares an identical protein structure with&#xD;
      plasma-derived C1INH. The rationale of the current trial is based upon the following&#xD;
      assumptions: In the context of COVID-19, conestat alfa treatment may 1) dampen uncontrolled&#xD;
      complement activation and collateral lung damage and 2) reduce capillary leakage and&#xD;
      subsequent pulmonary edema by direct inhibition of KK system. The aim of this study is to&#xD;
      analyze administration of conestat alfa for 72 hours in addition to standard of care in&#xD;
      patients hospitalized with non-critical SARS-CoV-2 pneumonia (WHO Ordinal Scale Score 3 or 4)&#xD;
      and its association with clinical severity on day 7 after inclusion and the risk of disease&#xD;
      progression to Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, open-label, parallel-group, controlled, multi-center clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease severity</measure>
    <time_frame>on day 7</time_frame>
    <description>Disease severity on the 7-point Ordinal World Health Organization (WHO) scale (for the current study, score 0 will be omitted and score 6 and 7 will be combined). The ordinal scale measures illness severity over time. This endpoint has been suggested by WHO for clinical trials in patients with COVID-19.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to clinical improvement</measure>
    <time_frame>within 14 days after enrolment</time_frame>
    <description>Time to clinical improvement (time from randomisation to an improvement of two points on the seven-category WHO ordinal scale or live discharge from hospital, whichever came first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants alive and not having required invasive or non-invasive ventilation</measure>
    <time_frame>at 14 days after enrolment</time_frame>
    <description>Proportion of participants alive and not having required invasive or non-invasive ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with an ALI (defined by PaO2/FiO2 ratio of &lt;300mmHg)</measure>
    <time_frame>within 14 days after enrolment</time_frame>
    <description>Proportion of subjects with an ALI (defined by PaO2/FiO2 ratio of &lt;300mmHg)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in the ordinal WHO scale</measure>
    <time_frame>from baseline over 14 days</time_frame>
    <description>Changes in the ordinal WHO scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of hospital stay in survivors</measure>
    <time_frame>until day 28</time_frame>
    <description>Length of hospital stay in survivors</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of participants progressing to mechanical ventilation</measure>
    <time_frame>on day 7 and day 14</time_frame>
    <description>Proportion of participants progressing to mechanical ventilation</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of participants requiring ICU treatment</measure>
    <time_frame>on day 7 and 14</time_frame>
    <description>Proportion of participants requiring ICU treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>until day 28</time_frame>
    <description>Length of ICU stay</description>
  </other_outcome>
  <other_outcome>
    <measure>28 Ventilator-free days</measure>
    <time_frame>until day 28</time_frame>
    <description>28 Ventilator-free days</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>time from randomisation to death within four weeks</time_frame>
    <description>All-cause mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in biomarker level CRP (mg/l)</measure>
    <time_frame>until day 14</time_frame>
    <description>Changes in biomarker level CRP</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in biomarker level LDH (U/l)</measure>
    <time_frame>until day 14</time_frame>
    <description>Changes in biomarker level LDH</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in biomarker level D- Dimer (yg/ml)</measure>
    <time_frame>until day 14</time_frame>
    <description>Changes in biomarker level D-Dimer</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in biomarker level Ferritin (ng/ml)</measure>
    <time_frame>until day 14</time_frame>
    <description>Changes in biomarker level Ferritin</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in biomarker level Interleukin 6 (IL- 6) (pg/ml)</measure>
    <time_frame>until day 14</time_frame>
    <description>Changes in biomarker level IL-6</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in lymphocyte count (cells per microliter of blood)</measure>
    <time_frame>until day 14</time_frame>
    <description>Changes in lymphocyte count</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to virological clearance of SARS-CoV-2 by PCR from upper or lower respiratory tract samples</measure>
    <time_frame>time from enrolment to first of 2 negative assays at least 12 hours apart</time_frame>
    <description>Time to virological clearance of SARS-CoV-2 by PCR from upper or lower respiratory tract samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients receiving additional anti-inflammatory treatment such as tocilizumab or immunoglobulins</measure>
    <time_frame>within 14 days</time_frame>
    <description>Proportion of patients receiving additional anti-inflammatory treatment such as tocilizumab or immunoglobulins</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to defervescence (temperature &lt;38.0°C)</measure>
    <time_frame>sustained for at least 48 hours</time_frame>
    <description>Time to defervescence (temperature &lt;38.0°C)</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to clinical improvement (defervescence, normalization of oxygen saturation (&gt;93%) and respiratory rate) until day 28</measure>
    <time_frame>until day 28</time_frame>
    <description>Time to clinical improvement (defervescence, normalization of oxygen saturation (&gt;93%) and respiratory rate)</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of supplemental oxygen</measure>
    <time_frame>until day 28</time_frame>
    <description>Duration of supplemental oxygen</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in pharmacokinetics of conestat alfa</measure>
    <time_frame>at baseline, day 1, day 3, day 7, day 10 (during admission) and day 14 (1/- 2days) or discharge date</time_frame>
    <description>Peak serum concentration of conestat alfa will be measured</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in pharmacodynamics of conestat alfa (C1-inhibitor (CI-INH) concentration)</measure>
    <time_frame>at baseline, day 1, day 3, day 7, day 10 (during admission) and day 14 (1/- 2days) or discharge date</time_frame>
    <description>Change in pharmacodynamics of conestat alfa (C1-inhibitor (CI-INH) concentration)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Coronavirus Infections</condition>
  <arm_group>
    <arm_group_label>active treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with conestat alfa in addition to standarf of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care treatment arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care treatment established at the centers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conestat alfa</intervention_name>
    <description>Conestat alfa (8400 Units (U) followed by 4200 U every 8 hours, 9 administrations in total) will be administered as a slow intravenous injection (5-10 minutes) over a 72 hour period.</description>
    <arm_group_label>active treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed Consent as documented by signature&#xD;
&#xD;
          -  admitted to the hospital because of confirmed (by a positive SARS-CoV-2 PCR result)&#xD;
             COVID-19 infection&#xD;
&#xD;
          -  evidence of pulmonary involvement on CT scan or X-ray of the chest (e.g. ground glass&#xD;
             opacities)&#xD;
&#xD;
          -  symptom onset within the previous 10 days, i.e. fever or one respiratory symptom&#xD;
             (patients presenting later may have already progressed to an inflammatory state that&#xD;
             is potentially not amenable to C1INH treatment) OR shortness of breath within the&#xD;
             previous 5 days&#xD;
&#xD;
          -  expected to remain an inpatient over the next three calender days from time of&#xD;
             enrolment&#xD;
&#xD;
          -  at least one additional risk factor for progression to mechanical ventilation: 1)&#xD;
             arterial hypertension, 2) &gt;50 years, 3) obesity (BMI&gt;30.0 kg/m2), 4) cardiovascular&#xD;
             disease, 5) chronic pulmonary disease, 7) chronic renal disease, 6) C-reactive protein&#xD;
             of &gt;35mg/L, 7) oxygen saturation at rest in ambient air of &lt;94%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to the class of drugs under study (C1 esterase inhibitor), e.g.&#xD;
             known hypersensitivity or allergy to class of drugs or the investigational product&#xD;
&#xD;
          -  Treatment with tocilizumab or another Il-6R or Il-6 inhibitor before enrolment&#xD;
&#xD;
          -  History or suspicion of allergy to rabbits&#xD;
&#xD;
          -  Women who are pregnant or breast feeding&#xD;
&#xD;
          -  Active or planned treatment with any other complement inhibitor&#xD;
&#xD;
          -  Liver cirrhosis (any Child-Pugh score)&#xD;
&#xD;
          -  Incapacity or inability to provide informed consent&#xD;
&#xD;
          -  Currently admitted to an ICU or expected admission within the next 24 hours&#xD;
&#xD;
          -  Currently receiving invasive or non-invasive ventilation&#xD;
&#xD;
          -  In the opinion of the treating time, death is deemed to be imminent and inevitable&#xD;
             within the next 24 hours&#xD;
&#xD;
          -  Participation in another study with investigational drug within the 30 days preceding&#xD;
             and during the present study with the following exemptions: 1) participation in&#xD;
             COVID-19 drug trials started at least 48 hours before admission (e.g. postexposure&#xD;
             prophylaxis with hydroxychloroquine) and 2) participation in COVID-19 drug trials&#xD;
             during ICU admission&#xD;
&#xD;
          -  Previous enrolment into the current study&#xD;
&#xD;
          -  Enrolment of the investigator, his/her family members, employees and other dependent&#xD;
             persons&#xD;
&#xD;
          -  Any uncontrolled or significant concurrent illness that would put the patient at a&#xD;
             greater risk or limit compliance with the study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Osthoff, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Basel, Division of Internal Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Osthoff, PD Dr. med.</last_name>
    <phone>+41 61 328 6828</phone>
    <email>michael.osthoff@usb.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Basel, Division of Internal Medicine</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Osthoff, PD Dr. med.</last_name>
      <phone>+41 61 328 6828</phone>
      <email>michael.osthoff@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Stephan Moser, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Michael Osthoff, PD Dr. med</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marten Trendelenburg, Prof. med</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Parham Sendi, Prof. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>June 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic hyperinflammation</keyword>
  <keyword>cytokine storm</keyword>
  <keyword>complement system</keyword>
  <keyword>kinin-kallikrein system</keyword>
  <keyword>C1 esterase inhibitor</keyword>
  <keyword>Conestat alfa</keyword>
  <keyword>Coronavirus Disease 19 (COVID-19)</keyword>
  <keyword>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement C1 Inhibitor Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

